Member Info for amones

Earlier today, tried to place a buy order in Barclays stock ISA accnt. Surprised to see the quote showing a stamp duty of 0.5%. Are AIM shares not excluded from stamp duty? Or, is HCM come out of AIM ‘very quietly’? Perhaps, more likely, a technical error at Barclays.

Let us hope, entry to HK stock exchange will be a significant event. Being the first Chinese company to research and develop cancer treatments in a China based pharmaceutical firm; will it be passionately received by investors (institutional and private) over there? As per yesterday’s sp, market valuation of 3.3 billion USD for a company with a good number of drugs in its pipeline, should be really attractive to investors in the second largest economy.

Thanks Davey, for the vital information. Regarding advantage of moving to LSE main listing, I remember reading years ago, on iii b.b, that it would enable many institutional investors to add HCM to their holdings. Such institutional investors are not allowed to buy AIM listed shares due to restrictions in their company policies. Not sure how accurate my memory is. Anybody who used to follow chi med on iii, please feel free to correct. Its another clever strategy by the management of proposed break up of London listed shares into ten shares. Those investors who are put off with a price tag of £48 might show interest if it is fiver!

My HCM shares are held in my stocks ISA. If HCM shares move over to main ftse 250 platform, would it affect investors like me? Investors like myself will be asked to sell the AIM shares and repurchase from the main listing? Another question; what percentage of the £ 3.12 billion market value of HCM is held as AIM shares? If most of HCM held as ADSs, does it matter if a small percentage to be traded on AIM?

Thanks warwis for correcting me. It was 3 years ago. I remember the sp dropping to some £19 for few months before climbing up like a rocket to £50+ with in couple of years.

Thanks JatW for explaining. When the company listed ADRs on NYSE, no additional/new shares were issued, if I remember correctly. Having not read yesterday’s company news release, properly, I assumed chi-med would be doing the same with its forthcoming HK stock exchange listing. Anyway, it’s a great step taken by the company. Investors from HK /(?and china) will be getting a chance to invest in their ‘own’ biotech company which has marketed the first oncology drug, fully developed in their own country. Well established commercial platform and many drug candidates in the pipeline should have greater positive impact. Wish the listing was done at the same time as the approval for fruquintinib from China authorities. It would have been a wonderful advertisement!

Is the company issuing new shares (400-600 million worth leading to dilution of market valuation) at the time of HK listing? In that case, yesterday’s market reaction should have been different. SP should have dropped significantly. Is the ‘issue’ of shares in addition to CKHH’s sale of part of its holding?

Market cap of HCM will be £13.34 billions, when sp reaches £200. Not very much, is it Davey?

Thanks Azurite. You have a fair point. Perhaps, this website’s software assumes a particular trade either as a sale or buy depending on the share price at any particular time.

Thanks Davey. Very nice of you for explaining the financial arrangements. Another major advantage to chi-med would be the positive impact on other drugs in the pipeline. Another issue that intrigues me; have you seen the numbers of ‘buys’ of significant quantity of shares after the market closure time? You can check these on ‘shares traded’ link here. Are these buys by institutional traders? It’s nice to see such buys. Who is/are these investors? Reasons for their confidence etc.,? overall looking good.

Oh! Sorry for my ignorance. Didn’t know that aspect of savolitinib. Davey, could please describe, briefly, how chi-med would be benefited, in case, savolitinib gets recognition in oncology therapeutics.

Davey, Thanks for the updates from AACR. Good to know savolitinib has been shown to be a useful combination, therapeutically. From your Friday’s message, “.... I think it is interesting in terms of how much AZ are willing to pay to get rights to the asset. I am not sure it has any direct impact on Savolitinib but it will be interesting to draw parallels in terms of how the market values assets like Savolitinib....” Very interesting! If AZ makes an offer for the rights on savolitinib, it will be a fantastic day for all long term HCM followers.

Over the last few weeks, significant numbers of ‘buys’ were shown on the shares traded link. This was following the ‘sell off’ and share price drop seen in December. Although, I was getting surprised at the level of confidence and optimism of those ‘buyers’, it was a matter of reassurance at the same time. Wondering if the progress report of studies mentioned in today’s news release has got anything to do with the confidence of such buyers! Just hoping!!

Total of 448,000 ADR shares traded yesterday on NYSE , with a small drop in share price. Not sure if that kind of volume is a norm. Hopefully, I am not the only holder having an uneasy feeling of nervousness, before Monday’s results. Consoling factor for me is the large volumes shown as buys in the shares traded link on this site, during the last few days.

Thank you, Davey. Interesting article, even though it’s from 2027. Nice to see share price crawling back to £40. Perhaps will cross 40 tomorrow, following today’s improvement in HCM ADRs on NYSE.

Thanks Davey for the additional information. As per the motley fool article, Tagrisso sales in 2018 was $1.9 billion, expected to raise to $5billion by 2022. Imfinzi brought in $633 million in first year, expected to grow to $2.8billion by 2023. Hopefully, Savolitinib (on its own, or in combination with Tagrisso and Imfinzi) will be added to the oncology therapeutics. HCM has many more drugs for oncology and autoimmune disorders in its pipeline. Majority owned by the multinational conglomerate CK Hutchison Holdings, employs 400 scientists and the market valuation is less than $3.5 billion! Which is less than predicted sales of Tagrisso in just one single year, 2022. Difficult to believe.

Error..Last sentence in my previous message should be...predicted 2022 sales valuation of Tagrisso, $5billion is more than today’s total market valuation of HCM...

‘2 Pharma Stocks in the Middle of an Oncology Sales Explosion’ dated 19/2/19. Quite interesting. There’s no mention of HCM. However, the bits written about AZN are about IMFINZI and TAGRISSO. the writer should have mentioned the CALYPSO and SAVANNAH studies in which HCM is fully involved. That should have surely made the article more worthy and rendered the rightful mention HCM deserves. The predicted sales of Tagrisso by 2022 is $5 billion. Just one drug is much more valued than today’s total market valuation of HCM which has several drug candidates in its pipeline.

The share price is recovering from the lows of £2.20 seen last October. How ever, this board has remained absolutely quiet for the last two months. Next set of results are due end of February. Any opinions about further improvements in share price?

Some reassurance to see significant purchase of hcm shares worth £ 655k going through yesterday afternoon. Appreciate the confidence of this trader. It would be nice to know the reason for this ‘confidence’ of this particular investor at this time. A polite request; ‘Please share your thoughts if you are that confident person!’ As Davey has written, this share needs some good news from the company so as to achieve last year’s valuation.